Skip to Content

Tag: OmniPod


Also Noted

Insulet posts Q4 revenue increase, net loss

February 24, 2021HME News Staff

ACTON, Mass. – Insulet  reported revenues of $246.1 million for the fourth quarter of 2020, an increase of 17.5% over the same quarter in 2019. Full-year revenues were $904.4 million, an increase of 22.5% compared to the previous year. For the quarter, U.S. Omnipod revenue was $231.1 million and International Omnipod revenue was $149.2 million. Omnipod revenue for the full year was $834.9 million: $526.9 million in U.S. Omnipod...

Diabetes, insulet, OmniPod


Read Full Articlered right arrow icon

Also Noted

Insulet extends financial assistance to 'Podders'

April 17, 2020HME News Staff

ACTON, Mass. - Insulet, maker of the OmniPod system, has expanded its U.S. financial assistance program for current customers who have been negatively impacted by COVID-19. Upon meeting certain financial criteria, those customers may receive up to a six-month supply (60 pods). “Our coronavirus response plan is guided by our fundamental principles of protecting the health and safety of our employees, preserving the well-being of the communities in which we live and work, and ensuring that customers...

Coronavirus Outbreak, insulet, OmniPod


Read Full Articlered right arrow icon

Specialty Providers

Insulet reports year-over-year growth

February 27, 2020HME News Staff

ACTON, Mass. - Insulet Corp. reported revenue of $738.2 million for 2019, a 31% increase compared to 2018. The company reported full-year revenue of $673.5 million for the Omnipod, broken down by U.S. revenue of $420.2 million and international revenue of $253.1 million, a 30% and 47% increase, respectively.Insulet reported revenue of $209.4 million for the fourth quarter of 2019, a 27% increase compared to the same period in 2018. Operating income was $18.2 million."2019 was a remarkable year for...

Diabetes, insulet, OmniPod


Read Full Articlered right arrow icon

Specialty Providers

Insulet reports positive net income for first time

February 26, 2019HME News Staff

ACTON, Mass. - Insulet Corp. has reported net income of $9.9 million for the fourth quarter of 2018 compared to a net loss of $6.9 million for the same period in 2017.The company reported net income of $3.3 million for all of 2018 vs. a net loss of $26.8 million for 2017.It's the first time in Insulet's history that the company has achieved full-year positive operating income and net income.“Insulet had a remarkable 2018, achieving our third consecutive year of over 20% revenue growth, significantly...

Financial Results, insulet, OmniPod


Read Full Articlered right arrow icon

Also Noted

Insulet reduces net loss

August 3, 2018HME News Staff

BILLERICA, Mass. - Insulet Corp., maker of the Omnipod Insulin Management System, reported revenues of $124.3 million for the second quarter, a 13% increase compared to the same period last year. It reported revenues of $78.1 million for the Omnipod in the U.S., a 19% increase. Insulet reported a net loss of $1.7 million for the second quarter compared to a net loss of $7.8 million for the same period last year. Among the company's highlights in the second quarter: It assumed direct European operations...

Financial Results, insulet, insulin, OmniPod


Read Full Articlered right arrow icon

Also Noted

Insulet: 'We are well on our way'

February 22, 2018HME News Staff

BILLERICA, Mass. - Insulet Corp. reported revenue of $130.5 million for the fourth quarter of 2017, an increase of 26% compared to the same period in 2016. U.S. revenue from the Omnipod was $76.5 million, an increase of 21%. Full-year revenue was $463.8 million and U.S. revenue from the Omnipod was $271.6 million. Among Insulet's highlights for 2017: It received Medicare coverage under the prescription drug benefit for the Omnipod, paving the way to capturing an additional one-third of the U.S. market;...

insulet, insulin pumps, OmniPod


Read Full Articlered right arrow icon

Also Noted

Insulet sees revenues increase across the board

November 3, 2017HME News Staff

BILLERICA, Mass. - Insulet Corp. reported revenues of $121.8 million for the third quarter of 2017, representing year-over-year growth of 28%. Net loss was 2.2 million. For the Omnipod, revenues in the U.S. were $70.1 million for the quarter, a 17% increase, and, internationally, $32.5 million, a 70% increase. Revenue from drug delivery was $19.2 million, a 19% increase. “We achieved strong third quarter results across all of our businesses, particularly in our international business,”...

diabetes technology, Insulet Corp, OmniPod


Read Full Articlered right arrow icon

E-SP

Diabetes in the news, in my life

February 2, 2017Theresa Flaherty, Managing Editor

CGMs are all around me. Ads for the Dexcom G5, in particular, keep popping up on websites. I am guessing this is because I Googled it while writing a story about Medicare's recent decision to start paying for certain CGMs (the Dexcom currently being the only one that meets the criteria at this time). I also met with a new CDE at the diabetes center this week. “Have you ever considered getting an insulin pump?” asked Sarah the CDE. (Syringes are so 1980s.) I get asked this every year or...

CGMs, Dexcom G5, insulin prices, insulin pump, OmniPod


Read Full Articlered right arrow icon

Specialty Providers

Earnings: Insulet in 'full swing' for 2016

March 21, 2016Theresa Flaherty, Managing Editor

BILLERICA, Mass. - Insulet Corp. execs stand poised to take advantage of the “tremendous market opportunity” for their wireless OmniPod system and other initiatives, they said in a recent earnings call.“We look forward to a very exciting 2016 of key initiatives in full swing and revenue that we expect to grow by approximately 30% compared to 2015,” said Patrick Sullivan, president and CEO. “We are highly focused on maximizing the future potential of our OmniPod technology.”The...

Diabetes, insulet, OmniPod


Read Full Articlered right arrow icon

Also Noted

Insulet reorganizes executive team

July 1, 2015HME News Staff

BILLERICA, Mass. - Patrick Ryan, former COO of Insulet, has resigned to “pursue other interests,” the company announced June 30. Other changes: Mark Licari has been promoted to vice president of global manufacturing and operations; and David Colleran, who joined Insulet June 29, will succeed Anthony Diehl as vice president and general counsel. Diehl also resigned. Licari and Colleran will report directly to Patrick Sullivan, president and CEO. "Looking forward, we are excited to leverage...

insulet, OmniPod


Read Full Articlered right arrow icon